JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Bimekizumab is a monoclonal antibody that targets interleukin (IL)-17A and IL-17F, cytokines involved in the inflammatory process. It was developed by UCB, a global biopharmaceutical company. Bimekizumab consists of a humanized IgG1 monoclonal antibody. Its mechanism of action involves dual inhibition of IL-17A and IL-17F, which helps reduce inflammation and modulate the immune response. It is primarily used to treat moderate to severe plaque psoriasis and is being studied for other inflammatory diseases such as psoriatic arthritis and ankylosing spondylitis.